Almost stubbornly, infectious diseases remain a major cause of morbidity and mortality. Even in developed countries, it is the third leading cause of death and, if anything, is rising relative to cardiovascular disease and cancer. Indeed, the lead article by Rice documents the need both for novel agents and to do our utmost to maintain the effectiveness of those agents currently used for antimicrobial therapy. Therefore, the overarching theme of this issue is the increased importance of prevention --- not just to prevent disease per se but also to help minimize the therapeutic use of anti-infective agents. Decreasing the use of anti-infectives is considered a key component in any program to limit the emergence and dissemination of resistant strains, as discussed by Rice. Furthermore, because the pipeline of novel agents is weak, there will be a premium placed on preventing the contraction of previously treatable infectious diseases for which there may no longer be a cure; the commercial, regulatory and societal reasons behind this are described in the review by Shlaes. One of the original televangelists, Frederick J Eikenrenkoetter (better known as 'The Reverend Ike'), has long preached that "the best thing you can do for the poor people is not be one of them". Likewise, the best thing we can do for sick people is not to be sick ourselves. This is elegantly demonstrated by Furuya and Lowy, who discuss the infectious hazards of cardiothoracic surgery and implanted devices, and the difficulties associated with treating these infections. They discuss current therapeutic practice for such infections (which is less efficacious than many realize) and also explore future directions. Perhaps most interestingly, they summarize recent data on the role of decolonization, which appears beneficial in cutting the infection rate for serious multidrug-resistant infections.

The reviews on the evolution of methicillin-resistant *Staphylococcus aureus* and *Helicobacter pylori* make for an interesting contrast. In his paper, Enright (who developed multi-locus sequence typing as an epidemiological tool) describes the high degree of clonality (i.e. relatedness) among strains of multidrug-resistant *S. aureus*, whereas Kuipers, Janssen and de Boer describe what appears to be a highly diverse population of *H. pylori* strains that colonizes a majority of adults. Although the authors do not take a firm position on screening and wholesale treatment of colonized individuals, their data suggest that such a course may well be justified. As more patients are being treated with antibacterials for *H. pylori* infection/colonization, it will be interesting to see if a highly clonal resistant subpopulation evolves (as has been the case with methicillin-resistant *Staphylococcus aureus*). The irony is that chemotherapeutic approaches to decolonization for disease prevention might lead to increased antimicrobial use and perhaps an increase in the dissemination of resistant strains.

So how does one prevent disease in what we know to be an at-risk population? In addition to decolonization with specific anti-staphylococcal agents (as discussed previously), passive immunization has also been attempted to prevent staphylcoccal infections in this population, and is reviewed in this issue by Dunman and Nesin. Indeed, these authors describe the current clinical use of a monoclonal antibody directed against respiratory syncytial virus, which they show to be superior to intravenous immunoglobulin treatment. However, the authors take this approach one step further by describing the potential use of colony-stimulating factors and other immunomodulators to augment immune function in immunosuppressed patients. As the population of people with various forms of immunosuppression increases, this therapy could form an important cornerstone of disease prevention.

A key component in the rational use of anti-infective agents will be the rapid and accurate diagnosis of the disease-causing entity. Van Belkum reviews the field of molecular diagnostics and indicates that such rapid diagnostics are certainly possible and, in some instances, practiced today, although culture methods will be with us for the foreseeable future. The author states that "molecular diagnostics has now \[passed from its infancy and\] definitely reached puberty".

One of the reasons for the weak pipeline of novel anti-infective drugs has been the lack of productivity of target-based drug discovery to identify novel agents. To date, not a single antibacterial agent that is being marketed was discovered by this approach. However, White, Margolis, Trias and Yuan describe work targeting metalloenzymes, most notably peptide deformylase, which has identified agents entering clinical trials. A key reason that many programs have failed to produce useful novel agents has been the 'red herring conundrum': target-based screening identifies agents with both activity against the target (most often in a cell-free system) and antimicrobial activity; however, at a later point in the drug discovery process, it is determined that the antimicrobial activity is unrelated to the activity against the original molecular target. Shaw and Morrow describe the uses of transcriptional profiling in anti-infective drug discovery, perhaps the most significant of which is in determining the mechanism of action of novel agents and allowing us to identify the red herrings earlier in the process and develop valid, as opposed to misleading, structure--activity relationships.

Apart from prevention or standard antimicrobial chemotherapy, other novel approaches at treatment involve targeting virulence (as opposed to the identification of frank growth inhibitors). Lee, Almqvist and Hultgren review our improving understanding of bacterial virulence, focusing on the prevention and treatment of urinary tract infections by targeting pilus assembly.

The points raised by Shlaes on the demise of anti-infective research deserve further comment here. The public pressures on the pharmaceutical industry are driving drug discovery towards commercially 'safer' products, as it is considered unseemly, by both the public and politicians alike, to make a profit on life-saving medications. Therefore, governments believe themselves morally justified to pursue the wholesale theft of intellectual property, with the result that more and more companies will focus on chronic rather than acute diseases (in fact, many have already done so). Perhaps the greatest irony of this phenomenon is that, as we become more effective at treating the diseases of ageing and prolonging life-spans, infectious disease are predicted to increase in significance. Indeed, this is already happening. Given that infectious agents disproportionately affect the elderly population, this most rapidly growing segment of our society are expected to become a vast reservoir of both current and emerging infectious agents. One would have hoped that the diminution of industrial interest in anti-infectives (coupled with an increased need to address infectious diseases) would be accompanied by increased levels of funding from governmental and non-profit groups. However, public support for infectious disease research is, at least in part, being siphoned off to study the detection, prevention and treatment of bioterrorism agents. Such a misappropriation of public funds (not to mention the valuable time of our best scientists and laboratories) to fight these perceived (dare I say artificial) threats, as opposed to dealing with the all too real threats we are confronted with in the here and now, means that the terrorists have won this battle. The lessons learnt from severe acute respiratory syndrome (SARS), West Nile Virus and pan-resistant bacterial infections are that the real bioterrorism agents are neither man-made nor spread intentionally, and dealing with such outbreaks requires robust public and private research in infectious diseases. This is an investment we can make now or we will most assuredly spend considerably more later. As Benjamin Franklin penned in *Poor Richard's Almanack*, "An ounce of prevention is worth a pound of cure".
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